Julho 2016 vol. 2 num. 7 - 13º Congresso Gaúcho de Clínica Médica

Artigo - Open Access.

Idioma principal

Perfil de Sensibilidade aos Antimicrobianos das Infecções Do Trato Urinário Adquiridas em Adultos e Idosos.

MICHELIN, Lessandra ; PETRY, Francine Lopes ; BOSI, Guilherme Rasia ; COMPARSI, Eduardo ; BETTIOL, Renata ; CHIARADIA, Fernanda de Oliveira ;

Artigo:

Introdução: Infecção do trato urinário (ITU) é uma das infecções mais frequentes encontradas em ambiente hospitalar e comunitário. Dentre os germes, os resistentes a multidrogas estão cada vez mais frequentes, conferindo limitação para o tratamento. Para a escolha do antibiótico no tratamento de ITU deve ser considerado fatores como eficácia, efeitos colaterais e perfil de sensibilidade local aos antimicrobianos. Objetivo: Analisar o perfil epidemiológico e de resistência bacteriana das ITU em consultas de pronto atendimento de três hospitais de Caxias do Sul, para determinar o melhor esquema terapêutico, enfatizando também a frequência e sensibilidade antimicrobiana das bactérias produtoras de ESBL.

Artigo:

Download (PDF)

Palavras-chave: infecção do trato urinário, infecção comunitária, infecção complicada,

Palavras-chave: ,

DOI: 10.5151/medpro-xiiicgcm-1457316784

Referências bibliográficas
  • [1] 1 Picozzi S,Ricci C, Gaeta M. Do we really know the prevalence of multi-drug resistance Escherichia coli in the territorial and nosocomial population? Urol Ann 2013; 5: 25-9
  • [2] Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2011; 169:1-38.
  • [3] Mireles ALF, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Reviews, 2015; 13: 269-84.
  • [4] Dalbosco V, Srougi M, Dall´Oglio M, et al. Infecções do Trato Urinário. Rev Bras Med. 2003;60(6):320-36.
  • [5] Santana TCFS, Pereira EMM, Monteiro SG,et al. Prevalência e Resistência Bacteriana aos Agentes Antimicrobianos de Primeira Escolha nas Infecções do Trato Urinário no Município de São Luis MA. Revista de Patologia Tropical. 2012; 41(4):409-18.
  • [6] Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5):e103-20.
  • [7] 7 Bergeron MG. Treatment of pyelonephritis in adults. Med Clin North Am 1995; 79:619-45)
  • [8] Foxman, B. Urinary Tract Infection syndromes: ocurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis. Clin. North Am. 2014; Vol 28: 1-13.
  • [9] Takhar S, Moran GJ. Diagnosis and Management of Urinary Tract Infection in the Emergency Department and Outpatient Settings. Infect Dis Clin N Am 2014; 28:33-48.
  • [10] Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004; 38-46.
  • [11] Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprimsulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis. 2002; 34(8):1061-6.
  • [12] Neal D E. Complicated urinary tract infections. Urol Clin North Am. 2008; Vol 35: 13-22
  • [13] Abrahamian FM, Krishnadasan A, Mower WR, et al. The association of antimicrobial resistance with cure and quality of life among women with acute uncomplicated cystitis. Infection. 2011; 39: 507-14
  • [14] Cohen ML. Changing patterns of infectious disease. Nature. 2000; 406(6797):762-7
  • [15] Bauza E, Cercenado E. Klebsiella and Enterobacter Antibiotic resistance and treatment implications. Semin Respis Infecti. 2002; 17:215-30.
  • [16] Zilberberg MD, Shorr AF. Secular trends in Gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009 Infect Control Hosp Epidemiol, 2013; 34. 940–46
  • [17] 17 Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol. 2001; 14: 933-51.
  • [18] Minarini LA, Gales AC, Palazzo IC, et al. Prevalence of community-occurring extend-spectrum-Beta-Lactamase- producing Enterobacteriacea in Brazil. Current Microbiology 2007; 54: 335-341
  • [19] Paterson DL, Bonomo RA (2005) Extended-spectrum betalactamases: a clinical update. Clin Microbiol Rev 18: 657-86.
  • [20] Poole K. Resistance to β -Lactam antibiotics. Cell. Mol. Life Sci. 2004; 61(17):2200–23.
  • [21] Bonnet R. “Growing group of extended-spectrum β-lactamases: the CTX-M enzymes, ”Antimicrobial Agents and Chemotherapy. 2004; 48(1):1–14. [PMC free article] [PubMed]
  • [22] Perez F, Endimiani A, Hujer KM, et al. “The continuing challenge of ESBLs,” Current Opinion in Pharmacology. 2007; 7(5):459–69. [PMC free article] [PubMed]
  • [23] Paterson DL, Hujer KM, Hujer AM, et al. “Extended-spectrum b-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type b-lactamases.” Antimicrob Agents Chemother. 2003; 47:3554–60.[PMC free article] [PubMed]
  • [24] Cho YH, Jung SI, Chung HS, et al. Antimicrobial susceptibilities of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae in health care associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol.2005; 47(7):1059-66.
  • [25] 25 ECDC (2011) Annual epidemiological report. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Reporting on 2009 surveillance data and 2010 epidemic intelligence data: 183–5.
  • [26] Leistner R, Meyer E, Gastmeier P, et al. Risk Factors Associated with the Community-Acquired Colonization of Extended-Spectrum Beta-Lactamase (ESBL) Positive Escherichia Coli. An Exploratory Case Control Study. Institute of Hygiene and Environmental Medicine. PLoS ONE 8(9): e74323.
  • [27] Silva. K, Lincopam N. Epidemiologia das betalactamases de espectro estendido no Brasil: impacto clínico e implicações para o agronegócio. .J Bras Patol Med Lab2012.48 (2): 91-9.
  • [28] Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin,cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratiamarcescens. Infection 1983 11: 315-17. 29. Blanchardièrea.A, Dargère S, Guérin F,et.al. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae Médecine et Maladies Infectieuses. 2015; 45(5):169–72
  • [29] 30. Bem-Ami R, Baño JR, Arslan H, et al. A Multinational Survey of Risk Factors for Infection with Extended-Spectrum Beta-Lactamase- Producing Enterobacteriaceae in Nonhospitalized Patients. Clinical Infectious Deseases 2009; 49: 682-90
  • [30] 31. Woerther PL, Burdet C, Chachaty E, et al. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26:744-52.
  • [31] 32. Heilberg IP, Schor N. Abordagem diagnostica e terapêutica na infecção do trato Urinário (ITU). Rev Assoc Bras Med. 2003; 49(1):109-16.
  • [32] 33. Czaja CA, Scholes D, Hooton TM, Stamm WE, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007 Aug 1; 45(3):273-80.
  • [33] 34. Echols RM, Tosiello RL, Haverstock DC, et al. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29: 113-19
  • [34] 35. Martins F, Vitorino J, Abreu A, et al. Avaliação do Perfil de susceptibilidade aos antimicrobianos de microrganismos isolados em urinas na Região do Vale do Sousa e Tâmega. Acta Med Port 2010; 23: 641-46
  • [35] 36. Francesco MA, Ravizzola G, Peroni L, et al. Urinary tract infections in Brescia, Italy: Etiology of uropathogens and antimicrobial resistance of common uropathogens. Med Sci Monit 2007; 13: 136-144
  • [36] 37. ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol. 2008; 111(3):785-94
  • [37] 38. Munoz-Davila M. Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections. Antibiotics. 2014; 3(1):39-48.
  • [38] 39. McKinnell JA, Stollenwerk NS, Jung CW, et al. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc. 2011; 86(6):480-8.
  • [39] 40. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003; 17:303-32.
  • [40] 41. Wiedemann B, Heisig A, Heisig P. Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects. Antibiotics 2014; 3(3):341-52.
  • [41] 42. Guneysel O, Onur O, Erdede M, et al. Trimethoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med. 2009 May;36(4):338-41
  • [42] 43. Wright SW, Wrenn KD, Haynes MLRN. Trimethoprim-Sulfamethoxazole Resistance Among Urinary Coliform Isolates. Journal of General Internal Medicine. 1999; 14(10):606-9.
  • [43] 44. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002 May 1; 34(9):1165-9.
  • [44] 45. Schoevaerdts D, Bogaerts P, Grimmelprez A, et al. Clinical profiles of patients colonize for infected with extended-spectrum beta-lactamase producingEnterobacteriaceae isolates: a 20-month retrospective study at a Belgian University Hospital. BMC Infectious Diseases 2011; 11:12-22
  • [45] 46. Wu UI, Yang CS, Chen WC, et al. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase- producing Escherichia coli. Journal of Microbiology, Immunology and infection 2010; 43: 310-16.
  • [46] 47. Rice, L.B, S H Willey, G A Papanicolaou, et al., Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusets chronic-care facility. Antimicrob. Agents Chemother.1990, 34: 2193-9.
  • [47] 48. Spadafino. J, Cohen B, Liu J, et al. Temporal trends and risk factors for extendedspectrum Beta-lactamase-producing E. Coli in adults with cateter-associated urinary tract infections. Antimicrobial Resistance and Infection Control 2014; 3:39-42.
  • [48] 49. Salles M.J.C, Zurita J, Mejía C, et al. Review Article. Resistant Gram-Negative infections in the outpatient setting in Latin America. Epidemiol. Infect. 2013;142:2459-72.
Como citar:

MICHELIN, Lessandra; PETRY, Francine Lopes; BOSI, Guilherme Rasia; COMPARSI, Eduardo; BETTIOL, Renata; CHIARADIA, Fernanda de Oliveira; "Perfil de Sensibilidade aos Antimicrobianos das Infecções Do Trato Urinário Adquiridas em Adultos e Idosos.", p. 13-36 . In: In Anais do 13º Congresso Gaúcho de Clínica Médica [=Blucher Medical Proceedings, n.7, v.2]. São Paulo: Blucher, 2016.
ISSN 2357-7282, DOI 10.5151/medpro-xiiicgcm-1457316784

últimos 30 dias | último ano | desde a publicação


downloads


visualizações


indexações